Biogen Targets Pediatric MS Growth With New Phase 3 Fumarate Study

Biogen Inc. (BIIB) announced an update on their ongoing clinical study.

Biogen Inc. (BIIB) has launched a Phase 3 trial called “A Phase 3 Study With an Open-Label Extension in Pediatric Participants to Evaluate the Safety, Efficacy, and Pharmacokinetics of Diroximel Fumarate and Dimethyl Fumarate for the Treatment of Relapsing Forms of Multiple Sclerosis.” The goal is to test how safe these oral drugs are in children, how well they reduce relapses, and why this pediatric data could extend Biogen’s multiple sclerosis franchise.

The study tests two Biogen drugs, diroximel fumarate and dimethyl fumarate, both oral treatments used to manage relapsing multiple sclerosis. They aim to reduce the number of relapses and brain lesions while offering a child friendly option compared with older drugs.

Children are split into groups by weight and then randomized to receive Biogen’s drugs or fingolimod, an established competitor therapy. Some parts of the study are blinded so neither families nor doctors know which drug is used, while others are open label, and the main purpose is treatment rather than diagnosis or prevention.

The trial is interventional and uses parallel groups, meaning different treatment arms run at the same time. It focuses on real world questions like relapse rates, side effects, growth and development, and simple safety checks investors can track once data starts to read out.

The study was first submitted on Feb. 26, 2026, showing this is a very recent pipeline move. The latest update was filed on Mar. 17, 2026, confirming the record is current even though recruitment has not yet started.

The trial is listed as not yet recruiting, so key dates like first patient in, primary completion, and final completion are still ahead and will likely stretch over several years. For investors, this means no near term revenue change, but a clear signal on Biogen’s long range plans in pediatric multiple sclerosis.

For the market, this update highlights Biogen’s effort to defend and extend its MS portfolio as older products face generic pressure. Positive long term pediatric data could support durable Vumerity and Tecfidera use, add label expansion potential, and improve visibility on Biogen’s cash flows.

The trial also puts Biogen in direct comparison with fingolimod, branded as Gilenya, which is associated with Novartis and generic players. If Biogen’s drugs show better safety or similar efficacy, that could slowly shift prescribing patterns in younger patients and support sentiment around BIIB versus rival MS platforms.

Investors should view this as an early but strategic move that may not move the stock in the short term, yet strengthens Biogen’s story in high need, niche MS segments. The recent update confirms the study is ongoing in setup with further operational and clinical details available on the ClinicalTrials portal.

To learn more about BIIB’s potential, visit the Biogen Inc. drug pipeline page.